Biotech Values

[DewDiligence]

POTP – Thanks for the correction re the interim alpha. 0.005 is still going to be tough to hit, but it’s obviously a lot easier than 0.002.

>is your statement about the limited information obtained from an interim data look dependent on the interim look being unscheduled? Because my recollection is of press releases going into more detail for some interim looks…<

The limited information from an interim look (i.e. getting only a halt vs continue decision) pertains to a trial that is blinded and is intended to remain blinded after the interim look. Many cancer trials are open-label, in which case this issue does not pertain. Whether an interim look is scheduled or unscheduled matters only if there is an SPA, which is not the case here. Regards, Dew